{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:35:32Z","timestamp":1790904932034,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["16132"],"award-info":[{"award-number":["16132"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children's Gaucher Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A number of genetic risk factors have been identified over the past decade for Parkinson\u2019s Disease (PD), with variants in <jats:italic>GBA<\/jats:italic> prominent among them. <jats:italic>GBA<\/jats:italic> encodes the lysosomal enzyme that degrades the glycosphingolipid, glucosylceramide (GlcCer), with the activity of this enzyme defective in Gaucher disease. Based on the ill-defined relationship between glycosphingolipid metabolism and PD, we now analyze levels of various lipids by liquid chromatography\/electrospray ionization-tandem mass spectrometry in four brain regions from age- and sex-matched patient samples, including idiopathic PD, PD patients with a <jats:italic>GBA<\/jats:italic> mutation and compare both to control brains (<jats:italic>n<\/jats:italic>\u2009=\u200921 for each group) obtained from individuals who died from a cause unrelated to PD. Of all the glycerolipids, sterols, and (glyco)sphingolipids (251 lipids in total), the only lipid class which showed significant differences were the gangliosides (sialic acid-containing complex glycosphingolipids), which were elevated in 3 of the 4 PD-GBA brain regions. There was no clear correlation between levels of individual gangliosides and the genetic variant in Gaucher disease [9 samples of severe (neuronopathic), 4 samples of mild (non-neuronopathic) <jats:italic>GBA<\/jats:italic> variants, and 8 samples with low \ufeffpathogenicity variants which have a higher risk for development of PD]. Most brain regions, i.e. occipital cortex, cingulate gyrus, and striatum, did not show a statistically significant elevation of GlcCer in PD-GBA. Only one region, the middle temporal gyrus, showed a small, but significant elevation in GlcCer concentration in PD-GBA. We conclude that changes in ganglioside, but not in GlcCer levels, may contribute to the association between PD and <jats:italic>GBA<\/jats:italic> mutations.<\/jats:p>","DOI":"10.1038\/s41531-022-00363-2","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T10:02:35Z","timestamp":1659780155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation"],"prefix":"10.1038","volume":"8","author":[{"given":"Shani","family":"Blumenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Nehushtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Or B.","family":"Barav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-3161","authenticated-orcid":false,"given":"Tamir","family":"Dingjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0013-0115","authenticated-orcid":false,"given":"Anthony H.","family":"Futerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"363_CR1","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak, L. A. et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain 140, 3191\u20133203 (2017).","journal-title":"Brain"},{"key":"363_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21144966","volume":"21","author":"S Blumenreich","year":"2020","unstructured":"Blumenreich, S., Barav, O. B., Jenkins, B. J. & Futerman, A. H. Lysosomal storage disorders shed light on lysosomal dysfunction in Parkinson\u2019s disease. Int. J. Mol. Sci. 21, 1\u201312 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"363_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino, R. & Schapira, A. H. V. Parkinson disease. Eur. J. Neurol. 27, 27\u201342 (2020).","journal-title":"Eur. J. Neurol."},{"key":"363_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/537S160a","volume":"537","author":"AH Futerman","year":"2016","unstructured":"Futerman, A. H. & Hardy, J. Finding common ground. Nature 537, 6\u20137 (2016).","journal-title":"Nature"},{"key":"363_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/1073858417748875","volume":"24","author":"R Balestrino","year":"2018","unstructured":"Balestrino, R. & Schapira, A. H. V. Glucocerebrosidase and Parkinson disease: Molecular, clinical, and therapeutic implications. Neuroscientist 24, 540\u2013559 (2018).","journal-title":"Neuroscientist"},{"key":"363_CR6","doi-asserted-by":"crossref","unstructured":"Futerman, A. H. & Zimran, A. Gaucher Disease (CRC Press, 2006).","DOI":"10.1201\/9781420005509"},{"key":"363_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska, K. S., LaMarca, M. E., Scott, C. R. & Sidransky, E. Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567\u2013583 (2008).","journal-title":"Hum. Mutat."},{"key":"363_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","volume":"39","author":"O Nilsson","year":"1982","unstructured":"Nilsson, O. & Svennerholm, L. Accumulation of glucosylceramide and glucosylsphingosine (Psychosine) in cerebrum and cerebellum in infantile and juvenile gaucher disease. J. Neurochem. 39, 709\u2013718 (1982).","journal-title":"J. Neurochem."},{"key":"363_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","volume":"72","author":"I Milenkovic","year":"2022","unstructured":"Milenkovic, I., Blumenreich, S. & Futerman, A. H. GBA mutations, glucosylceramide, and Parkinson\u2019s disease. Curr. Opin. Neurobiol. 72, 148\u2013154 (2022).","journal-title":"Curr. Opin. Neurobiol."},{"key":"363_CR10","doi-asserted-by":"publisher","unstructured":"Wallom, K.-L. et al. Glycosphingolipid metabolism and its role in ageing and Parkinson\u2019s disease. Glycoconj. J. https:\/\/doi.org\/10.1007\/s10719-021-10023-x (2021).","DOI":"10.1007\/s10719-021-10023-x"},{"key":"363_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0125204","volume":"10","author":"LN Clark","year":"2015","unstructured":"Clark, L. N. et al. Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease. PLoS One 10, 1\u201316 (2015).","journal-title":"PLoS One"},{"key":"363_CR12","doi-asserted-by":"publisher","unstructured":"Surface, M. et al. Plasma glucosylsphingosine in GBA1 mutation carriers with and without Parkinson\u2019s disease. Mov. Disord. https:\/\/doi.org\/10.1002\/mds.28846 (2021).","DOI":"10.1002\/mds.28846"},{"key":"363_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/ene.13927","volume":"26","author":"D Arkadir","year":"2019","unstructured":"Arkadir, D. et al. Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA-related Parkinson\u2019s disease. Eur. J. Neurol. 26, 1013\u20131018 (2019).","journal-title":"Eur. J. Neurol."},{"key":"363_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2017.00027","volume":"11","author":"A Ledonne","year":"2017","unstructured":"Ledonne, A. & Mercuri, N. B. Current concepts on the physiopathological relevance of dopaminergic receptors. Front. Cell. Neurosci. 11, 1\u20139 (2017).","journal-title":"Front. Cell. Neurosci."},{"key":"363_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0022-2275(20)39619-X","volume":"6","author":"JS O\u2019Brien","year":"1965","unstructured":"O\u2019Brien, J. S. & Sampson, E. L. Lipid composition of the normal human brain: Gray matter, white matter, and myelin. J. Lipid Res. 6, 537\u2013544 (1965).","journal-title":"J. Lipid Res."},{"key":"363_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0005-2760(73)90055-6","volume":"296","author":"G Tettamanti","year":"1973","unstructured":"Tettamanti, G., Bonali, F., Marchesini, S. & Zambotti, V. A new procedure for the extraction, purification and fractionation of brain gangliosides. Biochim. Biophys. Acta 296, 160\u2013170 (1973).","journal-title":"Biochim. Biophys. Acta"},{"key":"363_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF03160026","volume":"18","author":"M Chavko","year":"1993","unstructured":"Chavko, M., Nemoto, E. M. & Melick, J. A. Regional lipid composition in the rat brain. Mol. Chem. Neuropathol. 18, 123\u2013131 (1993).","journal-title":"Mol. Chem. Neuropathol."},{"key":"363_CR18","doi-asserted-by":"publisher","first-page":"108132","DOI":"10.1016\/j.celrep.2020.108132","volume":"32","author":"D Fitzner","year":"2020","unstructured":"Fitzner, D. et al. Cell-type- and brain-region-resolved mouse brain lipidome. Cell Rep. 32, 108132 (2020).","journal-title":"Cell Rep."},{"key":"363_CR19","doi-asserted-by":"crossref","unstructured":"Futerman, A. H. Biochemistry of Lipids, Lipoproteins, and Membranes (eds Ridgway, N. D. & McLeod, R. S.) 281\u2013316 (Elsevier Science, 2021).","DOI":"10.1016\/B978-0-12-824048-9.00009-2"},{"key":"363_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bcmd.2005.07.005","volume":"35","author":"E Beutler","year":"2005","unstructured":"Beutler, E., Gelbart, T. & Scott, C. R. Hematologically important mutations: Gaucher disease. Blood Cells, Mol. Dis. 35, 355\u2013364 (2005).","journal-title":"Blood Cells, Mol. Dis."},{"key":"363_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/hmg\/ddq454","volume":"20","author":"S Lesage","year":"2011","unstructured":"Lesage, S. et al. Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease. Hum. Mol. Genet. 20, 202\u2013210 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"363_CR22","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/acschembio.7b00276","volume":"12","author":"F Ben Bdira","year":"2017","unstructured":"Ben Bdira, F. et al. Stabilization of glucocerebrosidase by active site occupancy. ACS Chem. Biol. 12, 1830\u20131841 (2017).","journal-title":"ACS Chem. Biol."},{"key":"363_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2020.572965","volume":"14","author":"S Sipione","year":"2020","unstructured":"Sipione, S., Monyror, J., Galleguillos, D., Steinberg, N. & Kadam, V. Gangliosides in the brain: Physiology, pathophysiology, and therapeutic applications. Front. Neurosci. 14, 1\u201324 (2020).","journal-title":"Front. Neurosci."},{"key":"363_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"363_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00419","volume":"9","author":"LJ de Schipper","year":"2018","unstructured":"de Schipper, L. J. et al. Altered whole-brain and network-based functional connectivity in Parkinson\u2019s disease. Front. Neurol. 9, 1\u201310 (2018).","journal-title":"Front. Neurol."},{"key":"363_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker, M. et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol. Neurodegener. 14, 1\u201321 (2019).","journal-title":"Mol. Neurodegener."},{"key":"363_CR27","doi-asserted-by":"publisher","first-page":"175909141878188","DOI":"10.1177\/1759091418781889","volume":"10","author":"TN Seyfried","year":"2018","unstructured":"Seyfried, T. N. et al. Sex-related abnormalities in substantia nigra lipids in Parkinson\u2019s disease. ASN Neuro 10, 1759091418781889 (2018).","journal-title":"ASN Neuro"},{"key":"363_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.expneurol.2014.10.010","volume":"263","author":"P Hadaczek","year":"2015","unstructured":"Hadaczek, P. et al. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson\u2019s disease and GM1-deficient murine model. Exp. Neurol. 263, 177\u2013189 (2015).","journal-title":"Exp. Neurol."},{"key":"363_CR29","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg, M. E. et al. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085\u20131089 (2015).","journal-title":"Mov. Disord."},{"key":"363_CR30","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.3390\/nu7053891","volume":"7","author":"K Palmano","year":"2015","unstructured":"Palmano, K., Rowan, A., Guillermo, R., Guan, J. & McJarrow, P. The role of gangliosides in neurodevelopment. Nutrients 7, 3891\u20133913 (2015).","journal-title":"Nutrients"},{"key":"363_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ymgme.2019.05.005","volume":"128","author":"JT Saville","year":"2019","unstructured":"Saville, J. T., Flanigan, K. M., Truxal, K. V., McBride, K. L. & Fuller, M. Evaluation of biomarkers for Sanfilippo syndrome. Mol. Genet. Metab. 128, 68\u201374 (2019).","journal-title":"Mol. Genet. Metab."},{"key":"363_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1042\/AN20100021","volume":"2","author":"T Ariga","year":"2010","unstructured":"Ariga, T. et al. Ganglioside metabolism in a transgenic mouse model of alzheimer\u2019s disease: Expression of chol-1\u03b1 antigens in the brain. ASN Neuro 2, 233\u2013241 (2010).","journal-title":"ASN Neuro"},{"key":"363_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000338181","volume":"33","author":"Z Pernber","year":"2012","unstructured":"Pernber, Z., Blennow, K., Bogdanovic, N., M\u00e5nsson, J. E. & Blomqvist, M. Altered distribution of the gangliosides GM1 and GM2 in Alzheimer\u2019s disease. Dement. Geriatr. Cogn. Disord. 33, 174\u2013188 (2012).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"363_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymgme.2019.08.008","volume":"129","author":"JT Saville","year":"2020","unstructured":"Saville, J. T. & Fuller, M. Sphingolipid dyshomeostasis in the brain of the mouse model of mucopolysaccharidosis type IIIA. Mol. Genet. Metab. 129, 111\u2013116 (2020).","journal-title":"Mol. Genet. Metab."},{"key":"363_CR35","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.1007\/s00216-019-01989-7","volume":"411","author":"F Tobias","year":"2019","unstructured":"Tobias, F., Pathmasiri, K. C. & Cologna, S. M. Mass spectrometry imaging reveals ganglioside and ceramide localization patterns during cerebellar degeneration in the Npc1 \u2212\/\u2212 mouse model. Anal. Bioanal. Chem. 411, 5659\u20135668 (2019).","journal-title":"Anal. Bioanal. Chem."},{"key":"363_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ymgme.2017.12.432","volume":"123","author":"I Nestrasil","year":"2018","unstructured":"Nestrasil, I. et al. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study. Mol. Genet. Metab. 123, 97\u2013104 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"363_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.semcdb.2004.03.002","volume":"15","author":"SU Walkley","year":"2004","unstructured":"Walkley, S. U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 15, 433\u2013444 (2004).","journal-title":"Semin. Cell Dev. Biol."},{"key":"363_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21030868","volume":"21","author":"E Chiricozzi","year":"2020","unstructured":"Chiricozzi, E. et al. GM1 ganglioside is a key factor in maintaining the mammalian neuronal functions avoiding neurodegeneration. Int. J. Mol. Sci. 21, 1\u201329 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"363_CR39","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1074\/jbc.M114.585703","volume":"290","author":"G Marie","year":"2015","unstructured":"Marie, G. et al. Acceleration of \u03b1-synuclein aggregation by exosomes. J. Biol. Chem. 290, 2969\u20132982 (2015).","journal-title":"J. Biol. Chem."},{"key":"363_CR40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.bbapap.2018.07.004","volume":"1866","author":"R Gaspar","year":"2018","unstructured":"Gaspar, R., Pallbo, J., Weininger, U., Linse, S. & Sparr, E. Ganglioside lipids accelerate \u03b1-synuclein amyloid formation. Biochim. Biophys. Acta - Proteins Proteom. 1866, 1062\u20131072 (2018).","journal-title":"Biochim. Biophys. Acta - Proteins Proteom."},{"key":"363_CR41","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molcel.2004.08.029","volume":"15","author":"A Tessitore","year":"2004","unstructured":"Tessitore, A. et al. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell 15, 753\u2013766 (2004).","journal-title":"Mol. Cell"},{"key":"363_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.molcel.2009.10.021","volume":"36","author":"R Sano","year":"2009","unstructured":"Sano, R. et al. GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. Mol. Cell 36, 500\u2013511 (2009).","journal-title":"Mol. Cell"},{"key":"363_CR43","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1126\/science.277.5332.1652","volume":"277","author":"R De Maria","year":"1997","unstructured":"De Maria, R. et al. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science 277, 1652\u20131655 (1997).","journal-title":"Science"},{"key":"363_CR44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/WNR.0b013e32832e4b9d","volume":"20","author":"N Oikawa","year":"2009","unstructured":"Oikawa, N. et al. Gangliosides determine the amyloid pathology of Alzheimer\u2019s disease. Neuroreport 20, 1043\u20131046 (2009).","journal-title":"Neuroreport"},{"key":"363_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/jnc.13976","volume":"141","author":"JT Saville","year":"2017","unstructured":"Saville, J. T., Thai, H. N., Lehmann, R. J., Derrick-Roberts, A. L. K. & Fuller, M. Subregional brain distribution of simple and complex glycosphingolipids in the mucopolysaccharidosis type I (Hurler syndrome) mouse: Impact of diet. J. Neurochem. 141, 287\u2013295 (2017).","journal-title":"J. Neurochem."},{"key":"363_CR46","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/metabo11050294","volume":"11","author":"A Apffel","year":"2021","unstructured":"Apffel, A., Zhao, L. & Sartain, M. J. A novel solid phase extraction sample preparation method for lipidomic analysis of human plasma using liquid chromatography\/mass spectrometry. Metabolites 11, 294 (2021).","journal-title":"Metabolites"},{"key":"363_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/path.4992","volume":"244","author":"NJC Smith","year":"2018","unstructured":"Smith, N. J. C., Fuller, M., Saville, J. T. & Cox, T. M. Reduced cerebral vascularization in experimental neuronopathic Gaucher disease. J. Pathol. 244, 120\u2013128 (2018).","journal-title":"J. Pathol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00363-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00363-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00363-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:22:06Z","timestamp":1669299726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00363-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00363-2","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"6 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}